Reported impact
Business outcome
Deloitte boosted developer productivity by 50 percent, saved 7–10 months of multi-node infrastructure work, reduced training runs from four weeks to eight hours, and shrank pipeline assembly from 4–6 weeks to a few clicks while enabling richer molecular ranking and generation workflows for drug discovery.
- Cost Reduction
- Productivity Improvement
- Speed to Market
Solution
Deloitte built Quartz Atlas AI on NVIDIA DGX Cloud running on Oracle Cloud Infrastructure to turn multimodal drug-discovery research into a scalable, reusable pipeline. Atlas AI combines LLM-powered knowledge graphs, NVIDIA BioNeMo microservices, and Deloitte’s proprietary generative models to ingest sources such as PubMed, UniProt, antibody datasets, and small-molecule datasets into a 12-million-node, 97-million-edge graph totaling 5 TB of raw data. The platform uses AlphaFold2, OpenFold, and ESMFold for structure prediction, MegaMolBART and MolMIM for molecule generation, and DGX Cloud-based multi-node training to fine-tune protein and chemistry models such as a 15B-parameter ESM2 variant. NIM microservices then serve those models at scale so researchers can rank compounds, refine proteins, run inference loops, and generate comprehensive reports without manually wiring infrastructure or debugging bespoke pipelines for every experiment.
Data flow
Scientific literature, protein, antibody, and small-molecule datasets are loaded into Quartz Atlas AI, DGX Cloud trains BioNeMo and Deloitte models on the multimodal graph, NIM serves structure and molecule models such as AlphaFold2 and MolMIM, and researchers receive ranked compounds, predicted properties, and generated reports for downstream wet-lab decisions.